Study on Oxaliplatin with Chemotherapy and Radiation for Rectal Cancer
Author Information
Author(s): Sebag-Montefiore D, Glynne-Jones R, Falk S, Meadows H M, Maughan T
Primary Institution: Cancer Research UK
Hypothesis
What is the maximum tolerated dose of oxaliplatin when combined with 5-fluorouracil, leucovorin, and pelvic radiation in locally advanced rectal cancer?
Conclusion
The study found that the maximum tolerated dose of oxaliplatin is 150 mg/m², and the recommended dose is 130 mg/m², which shows promising results in treating locally advanced rectal cancer.
Supporting Evidence
- The maximum tolerated dose of oxaliplatin was determined to be 150 mg/m².
- 28 out of 32 patients completed all treatments as planned.
- Histopathology showed a complete pathological response in 7% of cases.
Takeaway
Doctors tested a new medicine called oxaliplatin with other treatments to help people with a type of bowel cancer. They found a safe amount to use that helps shrink the tumors.
Methodology
This was a dose escalation study where patients received oxaliplatin in combination with chemotherapy and radiation, with the maximum tolerated dose being determined based on observed toxicities.
Limitations
The study had a small sample size and was limited to a specific patient population with locally advanced rectal cancer.
Participant Demographics
Median age was 60 years, with 24 males and 8 females.
Statistical Information
Confidence Interval
95% CI 43–77%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website